Biodistribution studies of protein cage nanoparticles demonstrate broad tissue distribution and rapid clearance in vivo.
Protein cage nanoparticles have the potential to serve as multifunctional cell targeted, imaging and therapeutic platforms for broad applications in medicine. However, before they find applications in medicine, their biocompatibility in vivo needs to be demonstrated. We provide here baseline biodistribution information of two different spherical protein cage nanoplatforms, the 28 nm viral Cowpea chlorotic mottle virus (CCMV) and the 12 nm heat shock protein (Hsp) cage. In naive and immunized mice both nanoplatforms show similar broad distribution and movement throughout most tissues and organs, rapid excretion, the absence of long-term persistence within mice tissue and organs, and no overt toxicity after a single injection. These results suggest that protein cage based nanoparticles may serve as safe, biocompatible, nanoplatforms for applications in medicine.
Kaiser
Coleen R
CR
Department of Veterinary Molecular Biology, Montana State University, Bozeman, Montana, USA.
Flenniken
Michelle L
ML
Gillitzer
Eric
E
Harmsen
Ann L
AL
Harmsen
Allen G
AG
Jutila
Mark A
MA
Douglas
Trevor
T
Young
Mark J
MJ
D000818:Animals; D005260:Female; D008657:Metabolic Clearance Rate; D051379:Mice; D008807:Mice, Inbred BALB C; D053758:Nanoparticles / Q000737:chemistry* / Q000648:ultrastructure*; D009928:Organ Specificity; D010316:Particle Size; D011506:Proteins / Q000493:pharmacokinetics* / Q000648:ultrastructure*; D014018:Tissue Distribution
D011506:Proteins